Big moves lead to even bigger moves – that's the principle of momentum and it's one of the most powerful forces in the stock market.

I'll give you a textbook example of what I'm talking about. There's been a lot of buzz in the scientific community about the medicinal-mushroom market: Health Canada and the U.S. Food and Drug Administration have both approved the fast-tracking of research into the use of ketamine, psilocybin, and MDMA to treat mood disorders.

With that pivotal approval, the use of psychedelics to treat depression, anxiety, post-traumatic stress disorder (PTSD), and other issues can now be researched and developed – but the number of companies actually doing this is currently very limited.

The standout company in this space is Champignon Brands (CSE: SHRM, OTC: SHRMF), and their team features a premier network of clinicians and thought leaders throughout an ongoing series of campaigns and clinical trials.

Champignon is advancing medicines based on psychedelic substances through these planned and on-going clinical trials. A very early mover in the market, Champignon is currently working to assemble the most compelling portfolio, clinical pipeline, and drug development platform in the psychedelics space.

Even before the company's initial public offering, experts were anticipating the transformative impact that Champignon would have on the market. With around a million dollars of revenues in the company's first full year of operations, Champignon was a fast mover from the get-go.

This progress was soon reflected in the share price. SHRM stock shares commenced trading in March of this year, and early buyers of the IPO haven't regretted it. This is the kind of stock where you can keep adding to your position every time the price dips a little bit, since that's another chance to get in before it moves back up again.

Courtesy: barchart.com

You can see that shares gained 1,000% at one point but some inevitable profit-taking has occurred. That's normal for growth stocks and it's a chance to add to your position if you have one already, or to start a position in SHRM stock in anticipation of the next leg up.

Remember, the pathway for Champignon's progress has already been cleared. The FDA granted 'breakthrough therapy' status to research on ketamine and psilocybin remedies for mood disorders. Leading institutions have already indicated that psilocybin-assisted therapy could be a revolutionary treatment for depression, anxiety, and related issues.

That's clearance for more exciting research – and for investors to keep Champignon stock for the long term as the momentum is undeniable and the science irrefutable.


Consider becoming a shareholder of Champignon Brands (CSE: SHRM, OTC: SHRMF)!

For further updates on Champignon Brands​, subscribe now!

    We are not brokers, investment or financial advisers, and you should not rely on the information herein as investment advice. We are a marketing company. If you are seeking personal investment advice, please contact a qualified and registered broker, investment adviser or financial adviser. You should not make any investment decisions based on our communications. You should know that we have been compensated three hundred thousand dollars, directly by the company, for a two year public awareness campaign. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT recommendations. The securities issued by the companies we profile should be considered high risk and, if you do invest, you may lose your entire investment. Please do your own research before investing, including reading the companies’ SEC filings, press releases, and risk disclosures. Information contained in this profile was provided by the company, extracted from SEC filings, company websites, and other publicly available sources. We believe the sources and information are accurate and reliable but we cannot guarantee it.

    Please read our full disclaimer at WealthResearchGroup.com/disclaimer